louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04659720: Clinical Evaluation of Stability of Dental Implant Placed Simultaneously With Closed Sinus Lifting Using Hydraulic Lift Technique Versus Summer's Osteotome Technique in Posterior Edentulous Maxilla (RCT)
Official title: Clinical Evaluation of Stability of Dental Implant Placed Simultaneously With Closed Sinus Lifting Using Hydraulic Lift Technique Versus Summer's Osteotome Technique in Posterior Edentulous Maxilla (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Evaluations, Diagnostic Self
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-12-09
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical evaluation of stability of dental implant placed simultaneously with closed sinus lifting using hydraulic lift technique versus summer's osteotome technique in posterior edentulous maxilla (RCT)

Detailed description: Clinical evaluation of stability of dental implant placed simultaneously with closed sinus lifting using hydraulic lift technique versus summer's osteotome technique in posterior edentulous maxilla (Randomised clinical trial)

Eligibility criteria: Inclusion Criteria:

* Edentulous patients in the maxillary posterior region.
* Patients in need to fixed restorations in posterior region.
* Patients with healthy systemic conditions. (Apparently medically free)
* Patients with adequate inter-arch space for placement of the prosthetic part of the implant .
* Patients who had approximately 5-8 mm of available bone height between crest of bone and floor of sinus
* Both sexes.
* Patients with Good oral hygiene
* Patients more than 20 years old
* Cooperative and motivated patients

Exclusion Criteria:

* Patients with local pathological defects related to posterior maxilla.
* Heavy smokers.
* Abnormal habits that may alter results such as alcoholism or parafunctional habits.
* Patients with systemic diseases that may affect normal healing.
* Patients with psychiatric problem
* Patients with history of recent radiation therapy to the head and neck area.
* Patients with aggressive periodontitis.

Primary outcomes:
measure: Implant stability evaluation
timeFrame: Immediately after surgery
Secondary outcomes:
measure: Patient satisfaction evaluation
timeFrame: Immediately after surgery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo university
Study officials:
affiliation: Assoc.professor
name: Hassan Abdelghany, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04700020: An Assessment of the Occurrence of Hormone Deficiency in Patients With Empty Sella
Official title: (Partial) Empty Sella - Incidental Finding or the Cause of Hormonal Dysregulation?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Empty Sella
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2021-01-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this prospective study is to analyse the hormonal components in the blood of patients that were diagnosed with empty sella. Hereby we only take the hormones into consideration that are produced by the pituitary gland and/or are influenced by it due to positive/negative feedback. These are GH, ACTH, TSH, FSH, LH, PRL, oxytocine, ADH but also IGF-1, estradiol, testosteron, F4 and cortisol. The purpose is to see if abnormalities of the blook levels can be explained by the absence/shrinking of the pituitary gland. During this study, there will be a blood draw twice. The reason is to avoid wrong positive and negative results. Together with the second blood draw, there will be an insuline tolerance test in all patients. MRI will only be done if the last taken image is more than two years old or if the MRI was not taken with main focus on the pituitary gland.


Eligibility criteria: Inclusion Criteria:

* Patients that were diagnosed with an (partial) empty sella detected by MRI or CT of the brain have been included in this study. Whenever the MRI or CT scan was performed more than two years ago, a new MRI scan was required.

Exclusion Criteria:

* Children (patients less than 18 years) and patients with earlier diagnosed carcinomas of the brain as well as patients with secondary empty sella (antecedents of radiation, pharmacological treatment of pituitary adenomas, traumatic head injury and surgery of the pituitary gland as well as the central nervous system) were not included.

Primary outcomes:
measure: The proportion of patients that have hormone deficiency
timeFrame: Within two years after empty sella has been found on MRI or CT
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Universitair Ziekenhuis Brussel
state: Jette
Study officials:
References:
Clinical trial NCT00092820: Sitosterolemia Extension Study (0653-004)(COMPLETED)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lipid Metabolism, Inborn Errors
Heart Disease
Keywords: Homozygous Sitosterolemia
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2004-09-28
Enrollment: 58
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an extension study for patients having unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases. This study will evaluate the long term safety and the ability to lower cholesterol levels with an investigational drug.

Detailed description: The duration of treatment is 52 weeks.

Eligibility criteria: Inclusion Criteria:

* Patients with elevated sitosterol levels while taking current medication

Exclusion Criteria:

* Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.

Primary outcomes:
measure: Plasma sitosterol levels after 52 weeks.
Secondary outcomes:
measure: Plasma LDL-C and plasma campesterol. Safety and tolerability.
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B; Multicenter Sitosterolemia Study Group. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004 Mar 2;109(8):966-71. doi: 10.1161/01.CIR.0000116766.31036.03. Epub 2004 Feb 9.
citation: Lutjohann D, von Bergmann K, Sirah W, Macdonell G, Johnson-Levonas AO, Shah A, Lin J, Sapre A, Musliner T. Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J Clin Pract. 2008 Oct;62(10):1499-510. doi: 10.1111/j.1742-1241.2008.01841.x.
Clinical trial NCT00879320: Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder
Official title: Healthy Lifestyle in Adults With ADHD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ADHD
Attention Deficit Hyperactivity Disorder
Keywords: ADHD
health
healthy lifestyle
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Shire
First posted: 2009-04-10
Enrollment: 253
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults ages 18-55 who have ADHD (for ADHD group) Healthy adult volunteers ages 18-55 who do not have ADHD (control group)

Brief summary: The purpose of this study is to understand the relationship between ADHD and the overall health of someone with ADHD. People who have ADHD have trouble paying attention, concentrating, organizing, and planning. They may have trouble in school, at work, and at home. The investigators are interested in finding out whether these difficulties have had any influence in the past, current, or future health problems of someone with ADHD. About 100 people with ADHD and 100 people without ADHD will take part in this research study, all through Massachusetts General Hospital (MGH).


Eligibility criteria: Inclusion Criteria:

ADHD Subjects

1. Signed written informed consent to participate in the study.
2. Age: 18 - 60 (inclusive).
3. Current diagnosis of DSM-IV ADHD by structured interview. Late age of onset acceptable for participation provided ADHD symptoms meet full criteria currently.

Control Subjects

1. Signed written informed consent to participate in the study.
2. Age: 18 - 60 (inclusive).
3. Subjects must have \<3 symptoms in each domain (Inattention and Hyperactive/Impulsive) and \<5 total symptoms in both domains on the DSM-IVADHD module of the structured interview.

Exclusion Criteria:

1. Diagnosis of any psychotic disorder or Autism.
2. Mental impairment as evidenced by a Full Scale I.Q. less than 80.
3. Major sensorimotor handicaps such as deafness or blindness.
4. Subject currently taking antipsychotic medication or mood stabilizers.
5. Inadequate command of the English language.

Primary outcomes:
measure: Comparison of ADHD and control subject health habits will be assessed by subject-rated questionnaires and health measures, such as vital signs and blood draw results.
timeFrame: 1 time
Secondary outcomes:
Other outcomes:
Locations:
city: Cambridge
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Thomas Spencer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00573820: Far Infrared Radiation Treatment for Prostate Cancer
Official title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Prostatic Neoplasms
Keywords: Tumors or cancer of the prostate
Cancer of Prostate
Cancer of the Prostate
Neoplasms, Prostate
Neoplasms, Prostatic
Prostate Cancer
Prostate Neoplasms
Prostatic Cancer
Lead sponsor: GAAD Medical Research Institute Inc.
Sponsor class: OTHER
First posted: 2007-12-14
Enrollment: 4
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A study to determine the use of far infrared radiation for the treatment of prostate cancer.

Detailed description: Our initial assessment indicates that electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to cure a number of diseases, including prostate cancer.

Eligibility criteria: Inclusion Criteria:

* Persons with Prostate, Bladder or Testicular Cancer.

Exclusion Criteria:

* None

Primary outcomes:
measure: The primary end point is to determine the therapeutic effects of far infrared radiation on Prostate Cancer.
timeFrame: 2 years and 6 months
Secondary outcomes:
measure: The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of cancer (Bladder and Testis).
timeFrame: 2 years and 6 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Centre for Incurable Diseases
state: Ontario
Study officials:
affiliation: GAAD Medical Research Institute Inc.
name: Ken Nedd, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: GAAD Medical Research Institute Inc.
name: Kwasi Donyina, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00419120: Augmentation Cystoplasty Using an Autologous Neo-Bladder
Official title: An Open-Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Spina Bifida
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Neurogenic Bladder
Lead sponsor: Tengion
Sponsor class: INDUSTRY
First posted: 2007-01-08
Enrollment: 10
Sex: ALL
Minimum age (years): 3
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Subjects with neurogenic bladder secondary to spina bifida refractory to medical treatment will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will significantly increase bladder compliance.

Detailed description: Subjects with neurogenic bladder secondary to spina bifida (myelodysplasia) that is refractory to medical treatment and require augmentation cystoplasty will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will significantly increase bladder compliance.

Eligibility criteria: Inclusion Criteria:

* subjects with neurogenic bladders secondary to myleodysplasia

Exclusion Criteria:

* prior augment procedures
* recent urologic surgery
* requires concomitant urologic intervention

Primary outcomes:
measure: Number of Responders as Assessed by Compliance
timeFrame: 12 months
Secondary outcomes:
measure: Overall Safety Profile - Number of Participants Experiencing an Adverse Event
timeFrame: periodically within first 12 months as well as during long term follow up out to 5 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Childrens Hospital
state: Massachusetts
Study officials:
affiliation: Tengion, Inc.
name: Sunita Sheth, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00564720: Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
Official title: Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Pancreatic Cancer
Lead sponsor: Hellenic Oncology Research Group
Sponsor class: OTHER
Collaborators: name: University Hospital of Crete
First posted: 2007-11-28
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized phase II trial will compare the efficacy and toxicity of Gemcitabine plus Erlotinib versus Gemcitabine plus Erlotinib plus Oxaliplatin in patients with pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed pancreatic cancer.
* Measurable disease.
* Absence of ascites or obstructive jaundice.
* ECOG Performance Status 0-2.
* Adequate liver kidney and bone marrow function.
* Written informed consent.

Exclusion Criteria:

* Chronic diarrheic syndrome.
* Uncontrolled brain metastases after radiation.
* Liver infiltration over 50%.
* Peripheral neuropathy ≥ 2.
* No second primary malignancy within the past 5 years, except non-melanomas skin cancer or in situ carcinoma of the cervix.
* No active uncontrolled infection.
* Active cardiac disease : unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure \> class II, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
* Women who are pregnant or lactating.

Primary outcomes:
measure: Overall Survival
timeFrame: 1 year survival
Secondary outcomes:
measure: Progression free interval
timeFrame: 1 year
measure: Response rate
timeFrame: Objective responses confirmed by CT or MRI on 3rd and 6th cycle
measure: Toxicity profile
timeFrame: Toxicity assessment on each chemotherapy cycle
measure: Symptoms improvement
timeFrame: Assessment every two cycles
Other outcomes:
Locations:
city: Alexandroupolis
country: Greece
facility: University General Hospital of Alexandroupolis, Department of Medical Oncology
city: Athens
country: Greece
facility: Air Forces Military Hospital of Athens
city: Athens
country: Greece
facility: Errikos Ntynan General Hospital
city: Athens
country: Greece
facility: IASO General Hospital of Athens, 1st Department of Medical Oncology
city: Athens
country: Greece
facility: Laikon General Hospital, Medical Oncology Unit, Propedeutic Department of Internal Medicine
city: Athens
country: Greece
facility: Metaxa's Anticancer Hospital of Piraeus, 1st Department of Medical Oncology
city: Larissa
country: Greece
facility: State General Hospital of Larissa
city: Thessaloniki
country: Greece
facility: Diabalkaniko General Hospital of Thessaloniki
Study officials:
affiliation: University Hospital of Crete, Dep of Medical Oncology
name: Vassilis Georgoulias, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01734720: Common Bile Duct Stones - Natural History and Interventions
Official title: Common Bile Duct Stones - Natural History and Interventions : Data From the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangio Pancreatography (ERCP) (GallRiks)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Common Bile Duct Stone
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: Ersta Hospital, Sweden
First posted: 2012-11-28
Enrollment: 3828
Sex: ALL
Minimum age (years): 11
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing cholecystectomy with common bile duct stones found in peroperative cholangiogram

Brief summary: The aims of this study were to

1. investigate what measures were taken when common bile duct stones (CBDS) were found intraoperatively in Sweden during the period May 2005 to December 2009 by using data from this population-based nationwide registry, and
2. analyze the outcome in terms of complications and success rates of bile duct clearance in relation to various stone sizes and interventions used. In order to further characterize the natural course of CBDS of various sizes, particular interest was focused on patients with positive findings where no peroperative measures to clear the bile ducts were taken or planned postoperatively.


Eligibility criteria: Inclusion Criteria:

* common bile duct stones

Exclusion Criteria:

* none

Primary outcomes:
measure: complications in relation to strategy for handling CBDS
timeFrame: 30 days post operative
Secondary outcomes:
measure: complications in relation to stone size
timeFrame: 30 days post operative
Other outcomes:
Locations:
Study officials:
affiliation: Karolinsks Institutet
name: Mats Möller, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05845320: Prevalence of Stress Urinary Incontinence in Obese Versus Non-obese Nulligravid Women
Official title: Prevalence of Stress Urinary Incontinence in Obese Versus Non-obese Nulligravid Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stress Urinary Incontinence
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2023-05-06
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: healthy nulligravid females

Brief summary: Urinary incontinence (UI) is more common than any other chronic disease. Stress urinary incontinence (SUI), among the various forms of urinary incontinence, is the most prevalent (50%) type of this condition. Female urinary continence is maintained through an integrated function of pelvic floor muscles (PFMs), fascial structures, nerves, supporting ligaments, and the vagina. In women with SUI, the postural activity of the PFMs is delayed, and the balance ability is decreased. Many women, by learning the correct timing of a pelvic floor contraction during a cough, are able to eliminate consequent SUI. Timing is an important function of motor coordination and could be affected by proprioception.

We aim to assess stress urinary incontinence in obese and non-obese Nulligravid females.


Eligibility criteria: Inclusion Criteria:

* Women aged between18 and 45 years.
* Non obese females with BMI \<25kg/m2.
* Obese females with BMI ≥30kg/m2.
* Nulligravid females.

Exclusion Criteria:

* Multiparous Females
* Patients with active urinary tract infection.
* Patients with respiratory or neurological diseases.
* Patients with communication problems, cognitive disorders \& mental disturbance.
* Current treatment with drugs (benzodiazepines, diuretics)
* Patients who underwent any previous abdominal or pelvic surgery.

Primary outcomes:
measure: Prevalence of Stress Urinary Incontinence in Obese Versus Non-obese Nulligravid Women
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University maternity hospital
state: Cairo/القاهرة
Study officials:
affiliation: Associate professor
name: Maii Nawara, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05671120: Transcutaneous Levator Recession for Non-thyroid Lid Retraction
Official title: Transcutaneous Levator Recession for Non-thyroid Lid Retraction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eye Diseases
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2023-01-04
Enrollment: 19
Sex: ALL
Minimum age (years): 12
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This work aims to describe and assess the efficacy of transcutaneous levator palpebrea superioris muscle recession as a surgical procedure for treatment of upper lid retraction of various causes other than thyroid eye disease


Eligibility criteria: Inclusion Criteria:

* Patients suffering from upper eyelid retraction of various causes other than thyroid eye disease

Exclusion Criteria:

* Patients refused to participate in the study, patients with systemic diseases causing lid retraction (such as Guillain-Barré syndrome), pseudo retractions, contralateral ptosis, local skin condition (as scar adherence), medication (such as sympathomimetic drugs, lithium, and steroid), neurological conditions (such as dorsal midbrain syndrome and hydrocephalus) and thyroid related lid retraction

Primary outcomes:
measure: Margin reflex distance (MRD1)
timeFrame: Baseline
measure: Margin reflex distance (MRD1)
timeFrame: at one month post operative
Secondary outcomes:
Other outcomes:
Locations:
city: Damieta
country: Egypt
facility: Ehab tharwat
state: New Damietta
Study officials:
References: